RBC Capital Reiterates Outperform on Lexeo Therapeutics, Maintains $24 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated an Outperform rating on Lexeo Therapeutics (NASDAQ:LXEO) and maintained a $24 price target.
August 13, 2024 | 4:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated an Outperform rating on Lexeo Therapeutics and maintained a $24 price target.
The reiteration of an Outperform rating and the maintenance of a $24 price target by RBC Capital is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100